Clinical trial NCT00152477: A Study of Paclitaxel/Carboplatin With or Without CDP791 in Patients With Lung Cancer
Official title: A Two-Part, Open Label Phase II Trial: Part One, Dose Escalation Safety; Part Two, Randomized/Comparing CDP791 Plus Carboplatin/Paclitaxel With Carboplatin/Paclitaxel Alone in Subjects With Locally Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Carcinoma
Non-Squamous Non-Small-Cell Lung Cancer
Keywords: Non-small-cell-lung cancer
carboplatin
paclitaxel
VEGF
monoclonal antibody
Lead sponsor: UCB Pharma
Sponsor class: INDUSTRY
First posted: 2005-09-09
Enrollment: 165
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: A 2-part study to examine safety, tolerability and pharmacokinetics (part 1), and anti-tumour effects (part 2), of CDP791 combined with carboplatin and paclitaxel.

Detailed description: This is a two part study to investigate the safety and anti-tumour effects of standard chemotherapy, plus an investigational drug (CDP791), in patients with advanced non small cell lung cancer.

In part one, patients receive carboplatin and paclitaxel chemotherapy together with one of 2 doses of CDP791. The main aim of this part is to investigate safety and tolerability of carboplatin/paclitaxel plus CDP791.

If part one confirms that the combination of drugs is safe and well tolerated, 156 patients will enter part 2. They will be randomized to receive either carboplatin/paclitaxel (C/P) alone, or C/P plus one of 2 doses of CDP791. The main aim of this part of the study is to compare the anti-tumor effects of CDP791 plus C/T with those of C/T alone. Participants will receive up to six cycles of chemotherapy with or without CDP791. Those whose disease stabilizes, or responds, will be eligible to continue to receive CDP791. Participants in the C/T alone arm whose disease progresses will be eligible to receive CDP791 monotherapy.

Participants will be followed up longterm, so that survival can be measured.

Eligibility criteria: Inclusion Criteria:

Inclusion Criteria:

* Male and female subjects with Stage IIIb (with malignant pleural effusion or if no pleural effusion is present subjects who are not candidates for combined modality therapy), Stage IV, or recurrent non-squamous, non-small-cell lung carcinoma.
* The subject must be aged 18 years or above.
* The subject must have ECOG performance status of 0 or 1 and a life expectancy of at least three months.
* Subjects will have measurable disease.
* The subject must be able to understand the information provided to them and to give written informed consent.
* Female subjects must be either postmenopausal, surgically sterilized, or using a method of contraception judged reliable by the Investigator.
* Male subjects must be using a method of contraception judged reliable by the Investigator.

Exclusion Criteria:

* Subjects with squamous cell lung carcinoma.
* Subjects with lung lesions located centrally in the chest that involve major blood vessels.
* Concurrent active malignancy other than nonmelanoma skin cancer or carcinoma in situ of the cervix. Subjects with previous malignancies are eligible provided that they have been disease free for five years or more.
* Presence of additional major chronic disease such as hepatic or renal dysfunction, cardiac dysfunction, peripheral vascular disease, evidence of a myocardial infarction within six months of Screening visit, tuberculosis or epilepsy.
* Subjects known to be infected with hepatitis B or C virus or HIV 1 or 2.
* Any evidence of serious active infection (ie requiring an iv antibiotic or antiviral agent).

Exclusion Criteria:

Primary outcomes:
measure: Tumor Response Rate (RR)
timeFrame: 24 weeks
Secondary outcomes:
measure: Progression Free Survival (PFS)
timeFrame: Up to 57 weeks
measure: Time to Treatment Failure
timeFrame: Up to 57 weeks
measure: Overall Survival
timeFrame: Up to 57 weeks
measure: Duration of Overall Response
timeFrame: Up to 57 weeks
measure: Time to Response
timeFrame: Week 24
Other outcomes:
Locations:
city: Budapest
country: Hungary
city: Deszk
country: Hungary
city: Matrahaza
country: Hungary
city: Nyiregyhaza
country: Hungary
city: Pecs
country: Hungary
city: Krakow
country: Poland
city: Lodz
country: Poland
city: Lublin
country: Poland
city: Olsztyn
country: Poland
city: Otwock
country: Poland
city: Poznan
country: Poland
city: Radom
country: Poland
city: Szczecin
country: Poland
city: Torun
country: Poland
city: Warszawa
country: Poland
city: Wroclaw
country: Poland
city: Zabrze
country: Poland
city: Kazan
country: Russian Federation
city: Moscow
country: Russian Federation
city: Moskow
country: Russian Federation
city: Saint Petersburg
country: Russian Federation
city: Samara
country: Russian Federation
Study officials:
affiliation: UCB (+1 844 599 2273)
name: UCB Cares
role: STUDY_DIRECTOR
References: